Moreover, by categorising the patients into those that subsequently developed either local or distant cancer recurrence we were able to demonstrate that USP17 levels were higher in NSCLC patients whose disease had metastasised to distant sites including the adrenal glands, liver, brain, and bone. Here, USP17L9P is linked to cancer.